Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Thoughts on pan can deal

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jun 23, 2023 8:50pm

171 Views

Post# 35512404

RE:RE:RE:Thoughts on pan can deal

Listen to Dr. Shubham Pant of MD Anderson at the PanCan link provided who talks about immunotherapy, KRAS and turning cold tumors "hot" as pelareorep is capable of accomplishing in the treatment of pancreatic cancer.

Furthermore the Phase 3 adaptive trial design being applied in the pelareorep trial allows for fewer patient enrollment numbers due to biomarkers and next generation sequencing tests (somatic testing), as examples.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario